Bone Targeted Agents in Metastatic Prostate Cancer: Denosumab, Bisphosphonates and Radium-223 - Noel Clarke

This video lecture presentations took place at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), in Lisbon, Portugal between in October 2016.  The meeting was organised by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.

Noel Clarke, MD, discusses the biology of different bone targeted agents in metastatic prostate cancer and concludes that active drugs are available and safe and the combination of therapies are safe and potentially beneficial. 

Biography:
Noel Clarke has been a consultant urologist at Salford Royal Hospital and The Christie, Manchester, since 1993 and was made honorary professor of urological oncology by Manchester University in 1997. His specialist expertise is in prostate, bladder, renal and testis cancer and complex pelvic and retroperitoneal malignancy. Professor Clarke is a former director of urology at both Salford and The Christie, chair of the Manchester and Cheshire clinical study group (CSG) and National Cancer Research Institute prostate CSG. He is currently director of Manchester University’s Genitourinary Cancer Research Group, a member of the Department of Health and National Cancer Research Network prostate cancer advisory boards, chair of the European Organisation for Research and Treatment of Cancer prostate disease group and author of over 150 publications, including eight book chapters on urological cancer